| Company/Division name | Sino Biological |
| Parent company | Sino Biological |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2022 |
| Country(ies) from which reshored: | China |
| City reshored to: | Houston |
| State(s) reshored to: | TX |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | bioreagents and CRO services |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Infrastructure, Manufacturing/engineering joint innovation (R&D), Proximity to customers/market, Skilled workforce availability/training |
